Fennec Pharmaceuticals Inc (FENCF) 1.8800 $FENCF Fennec

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Fennec Pharmaceuticals Inc (FENCF) 1.8800 $FENCF

Fennec to Present at Rodman & Renshaw 17th Annual Global Investment Conference in New York on September 10, 2015
Marketwired - Thu Sep 03, 6:01AM CDT
Fennec Pharmaceuticals, Inc. (TSX: FRX)(OTCQB: FENCF), today announced that Rosty Raykov, CEO of Fennec, will present at the Rodman & Renshaw 17th Annual Global Investment Conference in New York City at 5:05 EDT on Thursday, September 10, 2015. The conference is being held at the St. Regis Hotel in New York City.
FRX.TO: 2.63 (-0.06)

Fennec Provides Corporate Update and Announces Second Quarter 2015 Financial Results
Marketwired - Tue Aug 11, 4:01PM CDT
Fennec Pharmaceuticals Inc. (TSX: FRX)(OTCQB: FENCF), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced ototoxicity in pediatric patients, today reported its financial results for the second quarter ended June 30, 2015.
FRX.TO: 2.63 (-0.06)

Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting
PR Newswire - Mon Jun 01, 10:00AM CDT
Fennec Pharmaceuticals, Inc. (TSX: FRX, OTCQB: FENCF), announced the presentation of positive interim results from a poster presented today entitled, "Anti-tumor efficacy in SIOPEL6: A multi-centre open label randomised phase III trial of the efficacy of sodium thiosulphate (STS) in reducing ototoxicity in patients receiving cisplatin (Cis) monotherapy for standard risk hepatoblastoma (SR-HB)." The data was presented at the American Society of Clinical Oncology (ASCO) 2015 Annual Meeting in Chicago. The poster is available today on the website http://fennecpharma.com/investors/presentations-events/.
FRX.TO: 2.63 (-0.06)

Fennec Announces Presentation of Positive Interim Sodium Thiosulfate Phase III Safety Data at the 2015 ASCO Annual Meeting
Marketwired - Sun May 31, 8:01PM CDT
Fennec Pharmaceuticals, Inc. (TSX: FRX) (OTCQB: FENCF), announced the presentation of positive interim results from a poster presented today entitled, "Anti-tumor efficacy in SIOPEL6: A multi-centre open label randomised phase III trial of the efficacy of sodium thiosulphate (STS) in reducing ototoxicity in patients receiving cisplatin (Cis) monotherapy for standard risk hepatoblastoma (SR-HB)." The data was presented at the American Society of Clinical Oncology (ASCO) 2015 Annual Meeting in Chicago. The poster is available today on the website http://fennecpharma.com/investors/presentations-events/.
FRX.TO: 2.63 (-0.06)

Fennec to Present at the Jefferies 2015 Global Healthcare Conference
Marketwired - Fri May 29, 5:01AM CDT
Fennec Pharmaceuticals Inc. (TSX: FRX)(OTCQB: FENCF) today announced that it will present at the Jefferies 2015 Global Healthcare Conference being held in New York City. Rosty Raykov, CEO, will provide an overview of the Company's business on Tuesday, June 2, 2015 at 11:30 a.m. (ET).
FRX.TO: 2.63 (-0.06)

Fennec Announces Results of Annual Meeting
Marketwired - Thu May 28, 7:29PM CDT
Fennec Pharmaceuticals Inc. (TSX: FRX)(OTCQB: FENCF) today announced that the nominees listed in the management proxy circular dated April 23, 2015 (the "Circular" for the Annual Meeting of Shareholders were elected as directors of the Company at the Annual Meeting of Shareholders held in Durham, North Carolina on May 28, 2015 (the "Meeting" . Detailed results of the vote for the election of directors are set out below:
FRX.TO: 2.63 (-0.06)

Fennec Provides Corporate Update and First Quarter Ended March 31, 2015 Financial Results
Marketwired - Fri May 15, 6:01AM CDT
Fennec Pharmaceuticals Inc. (TSX: FRX)(OTCQB: FENCF), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced ototoxicity in pediatric patients, today reported its corporate developments and financial results for the first quarter ended March 31, 2015.
FRX.TO: 2.63 (-0.06)

Fennec Announces Availability of Siopel 6 Study Abstract for ASCO 2015 Meeting
Marketwired - Thu May 14, 5:01AM CDT
Fennec Pharmaceuticals, Inc. (TSX: FRX)(OTCQB: FENCF), today announced that sodium thiosulfate (STS) will be featured in the abstract titled "Anti-tumor efficacy in SIOPEL6: A multi-centre open label randomised phase III trial of the efficacy of sodium thiosulphate (STS) in reducing ototoxicity in patients receiving cisplatin (Cis) monotherapy for standard risk hepatoblastoma (SR-HB)." at the American Society of Clinical Oncology (ASCO) being held May 29 through June 2, 2014 in Chicago, IL. The abstract is available as of today on the website http://www.abstract.asco.org/.
FRX.TO: 2.63 (-0.06)

Fennec Pharmaceuticals Announces the Exercise of Warrants by the Company's Largest Shareholder and Provides Updated Corporate Capital Structure
Marketwire Canada - Mon May 04, 6:17AM CDT
Fennec Pharmaceuticals, Inc. (TSX:FRX)(OTCQB:FENCF), today reported that Southpoint Master Fund, LP ("Southpoint" , the Company's largest shareholder with 36.6% of Fennec's issued and outstanding shares has exercised 0.3 million warrants at a price of USD$1.50. Net proceeds from the exercise of the warrants are expected to be approximately USD$0.45 million to the Company. Further, 1.3 million warrants at a price of CAD$4.32 expired on April 30, 2015.
FRX.TO: 2.63 (-0.06)

Southpoint Files Early Warning Report in Connection With Exercise of Warrants in Fennec Pharmaceuticals Inc.
Marketwired - Wed Apr 29, 12:32PM CDT
Southpoint Master Fund, LP ("Southpoint" has acquired, by the exercise of 293,511 warrants of Fennec Pharmaceuticals Inc. ("Fennec" at an exercise price of USD$1.50 per warrant (which represents approximately CAD$1.80 per warrant, based on the Bank of Canada's noon rate of USD$1 = CAD$1.2021 on April 28, 2015), 293,511 common shares of Fennec (the "Transaction" . The shares acquired pursuant to the Transaction represent approximately 2.8% of the issued and outstanding common shares of Fennec. The common shares were issued from Fennec's treasury.

Fennec Pharmaceuticals Provides Corporate Update and Fiscal Year Ended December 31, 2014 Financial Results
Marketwired - Wed Apr 01, 6:31AM CDT
Fennec Pharmaceuticals Inc. (TSX: FRX)(OTCQB: FENCF), a clinical stage biopharmaceutical company focused on the development of sodium thiosulfate (STS) for the prevention of ototoxicity from cisplatin in pediatric patients, today reported its corporate update and financial results for the year ended December 31, 2014. All amounts are in US dollars unless otherwise specified.
FRX.TO: 2.63 (-0.06)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 380

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
KINGRVER Boosts RV Comfort with New Water Heater Lineup

Updated Category News Views 328

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 258

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 459

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 131

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 157

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
FFR's Michigan Milestone and Major Robotics Update

Updated Category News Views 121

Nobody's going to argue that breaking into new territories isn't a gamble, but sometimes you just need to roll the dice. FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR) is banking on their move with Aegis Ultra robots, making an academic splash at Central Michigan University. This isn't just about ticking off another state; it's about stacking the deck with new...

Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 332

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 509

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading
Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 250

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading

Top 5 Most Recently Viewed Articles

Atlanticus Holdings Celebrates Substantial Year-End Growth

Updated Category News Views 176

Impressive Financial Results for Atlanticus Holdings Atlanticus Holdings Corporation (NASDAQ: ATLC), known for empowering financial inclusivity through innovative technology, has reported remarkable achievements in its financial results for the fourth quarter and the full year ended December 31, 2024. The company served an impressive total of 3.7 million accounts,...

Continue Reading
Jonas Warrer Expands Stake in Gentoo Media: Key Insights

Updated Category News Views 262

Jonas Warrer's Strategic Move in Gentoo Media Holdings Recent transactions in the stock market have captivated the attention of many investors, particularly when they involve significant figures in the industry. One such notable event occurred when Jonas Warrer, CEO and primary insider of Gentoo Media, made headlines by acquiring a substantial number of shares in his own...

Continue Reading
Venture Global Inc. Faces Class Action Over Investor Losses

Updated Category News Views 233

Venture Global Inc. Investors Advised on Class Action For investors in Venture Global Inc. seeking justice, significant legal developments have unfolded. The company, known for its ambitious initiatives in the liquefied natural gas sector, is currently facing serious allegations in a class action lawsuit. For those who lost money in their investments, it's crucial to...

Continue Reading
Global Roaming Tariff Market Expected to Hit USD 140.3 Billion

Updated Category News Views 329

Overview of the Roaming Tariff Market Growth The Roaming Tariff Market has entered an exciting phase, anticipated to soar to USD 140.3 billion by 2032, after reaching USD 77.5 billion in 2023. Such growth, at a compound annual growth rate (CAGR) of 6.83% from 2024 to 2032, is invigorated by the widespread expansion of 5G technology and increasing global travel demand. Key...

Continue Reading
Investing Insights: Analyzing Charles Schwab's Market Position

Updated Category News Views 263

Understanding the Recent Shift in Charles Schwab's Market Position Charles Schwab's short percent of float has recently experienced a significant increase, rising by 67.5% as indicated by the latest reports. Currently, there are 22.74 million shares sold short, which accounts for 1.34% of the total regular shares available for trading. With this short interest, traders...

Continue Reading